source
- FDA issues draft guidance for electronic IDE submissions via eSTARThe U.S. Food and Drug Administration released draft guidance outlining how sponsors can submit investigational device exemption (IDE) applications using the electronic Submission Template and Reso…
- Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trialThe highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.BioPharma Dive · 16d ago↗ source